J Exp Clin Cancer Res 2012, 31:79.PubMedCentralPubMedCrossRef Abemaciclib concentration 32. Shivarov V, Gueorguieva R, Stoimenov A, Tiu

R: DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients. Leuk Res 2013,37(11):1445–1450.PubMedCrossRef 33. Cikota BM, Tukic LJ, Tarabar OT, Magic ZM: Detection of t(14;18), P53 and RAS gene mutations and TSA HDAC quantification of residual disease in patients with B-cell non-Hodgkin’s lymphoma. J Exp Clin Cancer Res 2007,26(4):535–542.PubMed 34. Pichler M, Balic M, Stadelmeyer E, Ausch C, Wild M, Guelly C, Bauernhofer T, Samonigg H, Hoefler G, Dandachi N: Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn 2009,11(2):140–147.PubMedCentralPubMedCrossRef 35. Krypuy M, Newnham GM, Thomas DM, Conron M, Dobrovic A: High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer GNS-1480 mouse 2006, 6:295.PubMedCentralPubMedCrossRef 36. Ellison G, Donald E, McWalter G, Knight L, Fletcher L, Sherwood J, Cantarini M, Orr M, Speake G:

A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 2010, 29:132.PubMedCentralPubMedCrossRef 37. Oakes CC, La Salle S, Trasler JM, Robaire B: Restriction digestion and real-time PCR (qAMP). Methods Mol Biol 2009, 507:271–280.PubMedCrossRef 38. Altimari GBA3 A, de Biase D, De Maglio G, Gruppioni E, Capizzi E, Degiovanni A, D’Errico A, Pession A, Pizzolitto S, Fiorentino M, Tallini G: 454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples. Onco Targets Ther 2013, 6:1057–1064.PubMedCentralPubMed 39. Ihle MA, Fassunke J, Konig K, Grunewald I, Schlaak M, Kreuzberg N, Tietze L, Schildhaus

HU, Buttner R, Merkelbach-Bruse S: Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer 2014, 14:13.PubMedCentralPubMedCrossRef Competing interests The authors declare that they have no competing interest. Authors’ contributions BR carried out design of the study and drafted the manuscript. BO and BIW conceived of the study, and participated in its design and coordination and helped to draft the manuscript. KA and CR carried out the molecular genetic studies. SA and SC participated in sample collection and sequencing. All authors read and approved the final manuscript.”
“Introduction Neuroendocrine neoplasms (NEN)s represent a heterogeneous group of neoplasms with distinct morphological and biological manifestations.